BioNexus Gene Stock Forecast - Simple Regression
| BGLC Stock | USD 3.22 0.15 4.89% |
The Simple Regression forecasted value of BioNexus Gene Lab on the next trading day is expected to be 3.39 with a mean absolute deviation of 0.15 and the sum of the absolute errors of 9.18. BioNexus Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast BioNexus Gene stock prices and determine the direction of BioNexus Gene Lab's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of BioNexus Gene's historical fundamentals, such as revenue growth or operating cash flow patterns.
At the present time the relative strength index (rsi) of BioNexus Gene's share price is below 20 suggesting that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Quarterly Earnings Growth (0.95) | Quarterly Revenue Growth (0.03) |
Using BioNexus Gene hype-based prediction, you can estimate the value of BioNexus Gene Lab from the perspective of BioNexus Gene response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Regression forecasted value of BioNexus Gene Lab on the next trading day is expected to be 3.39 with a mean absolute deviation of 0.15 and the sum of the absolute errors of 9.18. BioNexus Gene after-hype prediction price | USD 3.23 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of BioNexus Gene to cross-verify your projections. BioNexus Gene Additional Predictive Modules
Most predictive techniques to examine BioNexus price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for BioNexus using various technical indicators. When you analyze BioNexus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
BioNexus Gene Simple Regression Price Forecast For the 25th of January
Given 90 days horizon, the Simple Regression forecasted value of BioNexus Gene Lab on the next trading day is expected to be 3.39 with a mean absolute deviation of 0.15, mean absolute percentage error of 0.03, and the sum of the absolute errors of 9.18.Please note that although there have been many attempts to predict BioNexus Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that BioNexus Gene's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
BioNexus Gene Stock Forecast Pattern
| Backtest BioNexus Gene | BioNexus Gene Price Prediction | Buy or Sell Advice |
BioNexus Gene Forecasted Value
In the context of forecasting BioNexus Gene's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. BioNexus Gene's downside and upside margins for the forecasting period are 0.20 and 6.59, respectively. We have considered BioNexus Gene's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of BioNexus Gene stock data series using in forecasting. Note that when a statistical model is used to represent BioNexus Gene stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 114.7175 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.1505 |
| MAPE | Mean absolute percentage error | 0.0353 |
| SAE | Sum of the absolute errors | 9.1779 |
Predictive Modules for BioNexus Gene
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioNexus Gene Lab. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BioNexus Gene After-Hype Price Prediction Density Analysis
As far as predicting the price of BioNexus Gene at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in BioNexus Gene or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of BioNexus Gene, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
BioNexus Gene Estimiated After-Hype Price Volatility
In the context of predicting BioNexus Gene's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on BioNexus Gene's historical news coverage. BioNexus Gene's after-hype downside and upside margins for the prediction period are 0.04 and 6.42, respectively. We have considered BioNexus Gene's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
BioNexus Gene is unstable at this time. Analysis and calculation of next after-hype price of BioNexus Gene Lab is based on 3 months time horizon.
BioNexus Gene Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as BioNexus Gene is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioNexus Gene backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with BioNexus Gene, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.69 | 3.19 | 0.01 | 2.11 | 8 Events / Month | 5 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
3.22 | 3.23 | 0.31 |
|
BioNexus Gene Hype Timeline
BioNexus Gene Lab is currently traded for 3.22. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of -2.11. BioNexus is expected to increase in value after the next headline, with the price projected to jump to 3.23 or above. The average volatility of media hype impact on the company the price is over 100%. The price growth on the next news is projected to be 0.31%, whereas the daily expected return is currently at -0.69%. The volatility of related hype on BioNexus Gene is about 104.38%, with the expected price after the next announcement by competition of 1.11. The company reported the previous year's revenue of 9.51 M. Net Loss for the year was (1.6 M) with profit before overhead, payroll, taxes, and interest of 1.4 M. Given the investment horizon of 90 days the next expected press release will be in about 8 days. Check out Historical Fundamental Analysis of BioNexus Gene to cross-verify your projections.BioNexus Gene Related Hype Analysis
Having access to credible news sources related to BioNexus Gene's direct competition is more important than ever and may enhance your ability to predict BioNexus Gene's future price movements. Getting to know how BioNexus Gene's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how BioNexus Gene may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ADVB | Advanced Biomed Common | 0.01 | 5 per month | 0.00 | (0.05) | 13.33 | (10.81) | 39.70 | |
| TRIB | Trinity Biotech plc | 0.02 | 4 per month | 5.30 | 0 | 12.86 | (6.82) | 64.13 | |
| CHEK | Check Cap | 0.01 | 8 per month | 6.07 | 0.12 | 17.16 | (10.37) | 198.26 | |
| APM | Aptorum Group Ltd | 0.14 | 16 per month | 0.00 | (0.17) | 4.46 | (6.87) | 28.25 | |
| XAIR | Beyond Air | 0.10 | 14 per month | 6.57 | 0.02 | 14.46 | (11.85) | 163.02 | |
| MBIO | Mustang Bio | 0.02 | 4 per month | 0.00 | (0.14) | 7.00 | (6.31) | 21.51 | |
| GLTO | Galecto | (28.66) | 2 per month | 7.44 | 0.12 | 17.97 | (14.66) | 273.14 | |
| LFWD | ReWalk Robotics | 0.08 | 4 per month | 4.22 | 0 | 10.14 | (6.58) | 34.28 | |
| LYRA | Lyra Therapeutics | (2.46) | 2 per month | 0.00 | (0.19) | 7.51 | (9.00) | 66.89 | |
| AEON | AEON Biopharma | 0.18 | 10 per month | 5.84 | 0.01 | 10.34 | (10.67) | 33.74 |
Other Forecasting Options for BioNexus Gene
For every potential investor in BioNexus, whether a beginner or expert, BioNexus Gene's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. BioNexus Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in BioNexus. Basic forecasting techniques help filter out the noise by identifying BioNexus Gene's price trends.BioNexus Gene Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioNexus Gene stock to make a market-neutral strategy. Peer analysis of BioNexus Gene could also be used in its relative valuation, which is a method of valuing BioNexus Gene by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
BioNexus Gene Market Strength Events
Market strength indicators help investors to evaluate how BioNexus Gene stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BioNexus Gene shares will generate the highest return on investment. By undertsting and applying BioNexus Gene stock market strength indicators, traders can identify BioNexus Gene Lab entry and exit signals to maximize returns.
BioNexus Gene Risk Indicators
The analysis of BioNexus Gene's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in BioNexus Gene's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting bionexus stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 2.42 | |||
| Standard Deviation | 3.17 | |||
| Variance | 10.06 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for BioNexus Gene
The number of cover stories for BioNexus Gene depends on current market conditions and BioNexus Gene's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that BioNexus Gene is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about BioNexus Gene's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
BioNexus Gene Short Properties
BioNexus Gene's future price predictability will typically decrease when BioNexus Gene's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of BioNexus Gene Lab often depends not only on the future outlook of the potential BioNexus Gene's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BioNexus Gene's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.8 M | |
| Cash And Short Term Investments | 4.4 M |
Check out Historical Fundamental Analysis of BioNexus Gene to cross-verify your projections. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.